ALSUntangled #68: ozone therapy

Sun, Yan; Barkhaus, Paul E.; Barnes, Benjamin; Beauchamp, Morgan; Benatar, Michael; Bertorini, Tulio E.; Bromberg, Mark B.; Carter, Gregory T.; Crayle, Jesse; Cudkowicz, Merit; Dimachkie, Mazen M.; Feldman, Eva L.; Fullam, Timothy; Heiman‐Patterson, Terry; Jhooty, Sartaj; Lund, Isaac; McDermott, Christopher J.; Pattee, Gary L.; Pierce, Kaitlyn; Ratner, Dylan; Wicks, Paul; Bedlack, Richard

doi:10.1080/21678421.2022.2145904

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The thickened liquid and oral film forms of Riluzole, Tiglutik and Exservan were later developed and approved by the FDA in 2018 and 2019, respectively. Nuedexta, the first FDAapproved drug for pseudobulbar affect, is a combination of quinidine sulfate and dextromethorphan hydrobromide that regulates neurotransmission in the central nervous system and showed positive effects on bulbar functions in ALS patients [24,25].. Radicava, a free-radical scavenger, acts to remove reactive oxygen species and reduce oxidative stress that was shown to be involved in ALS pathogenesis [26]. RELYVRIO, an oral combination of sodium phenylbutyrate and tauroursodeoxycholic acid that also targets reactive oxygen species and oxidative stress, is one of the latest FDA-approved drugs for ALS.…”

Section: Introduction To Alsmentioning

confidence: 99%

Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis

Nguyen

2024

Cells

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is a motor neuron disease. In ALS, upper and lower motor neurons in the brain and spinal cord progressively degenerate during the course of the disease, leading to the loss of the voluntary movement of the arms and legs. Since its first description in 1869 by a French neurologist Jean-Martin Charcot, the scientific discoveries on ALS have increased our understanding of ALS genetics, pathology and mechanisms and provided novel therapeutic strategies. The goal of this review article is to provide a comprehensive summary of the recent findings on ALS mechanisms and related therapeutic strategies to the scientific audience. Several highlighted ALS research topics discussed in this article include the 2023 FDA approved drug for SOD1 ALS, the updated C9orf72 GGGGCC repeat-expansion-related mechanisms and therapeutic targets, TDP-43-mediated cryptic splicing and disease markers and diagnostic and therapeutic options offered by these recent discoveries.

show abstract

Section: Introduction To Alsmentioning

confidence: 99%

Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis

Nguyen

2024

Cells

View full text Add to dashboard Cite

show abstract

ALSUntangled #68: ozone therapy

Cited by 1 publication

References 17 publications

Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis

Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis

Contact Info

Product

Resources

About